Salute e Benessere
Regenics AS appoints Jostein Grip as new CEO
Karin Gilljam, who has served as interim CEO for Regenics, will return to her role as company CSO and will be an integral part of the Regenics management team along with Jostein.
"We believe Jostein is an excellent choice for the CEO role and that he will be a strong addition to the Regenics team." said Jan A. Alfheim , Board Chair of Regenics. "His experience and knowledge in wound healing product development will be essential to the successful development of Collex™." The board would like to take this opportunity to extend our sincere gratitude to Karin Gilljam for her service as the company's interim CEO.
Collex is an advanced wound dressing designed to aid healing of partial thickness burns and chronic wounds, including diabetic and chronic vascular ulcers. With Collex Regenics aims to redefine the current standards of care in wound treatment.
Collex is a hydrogel wound dressing constructed with all-marine ingredients, sourced from the Norwegian coast. One of Regenics' major innovations, HTX™, is an essential component of Collex and is sourced and purified from unfertilized salmon roe. Collex is currently in the late pre-clinical stage, with significant beneficial effects on wound healing rates demonstrated.
Jan A. Alfheim , Board Chair
Cell: +47 46 44 00 45
Email: jal-alfh@online.no
or
Karin Gilljam, CEO
Cell: +47 91 80 98 87
Email: kg@regenics.no
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/regenics-as/r/regenics-as-appoints-jostein-grip-as-new-ceo,c4024310
View original content:https://www.prnewswire.co.uk/news-releases/regenics-as-appoints-jostein-grip-as-new-ceo-302459400.html